Status:
COMPLETED
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
Lead Sponsor:
Organon and Co
Conditions:
Osteoporosis, Postmenopausal
Eligibility:
FEMALE
40+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.
Eligibility Criteria
Inclusion
- Patient is postmenopausal (or surgically menopausal) for at least 6 months
- Patient must be diagnosed with osteoporosis
- Patient has spinal anatomy suitable for DEXA of the lumbar spine
Exclusion
- Patient is receiving or has received treatment prior to randomization which might influence bone turnover
- Patient has a history of or evidence for metabolic bone disease (other than postmenopausal bone loss)
- Patient is receiving or is expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism
Key Trial Info
Start Date :
April 2 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 16 2003
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00389740
Start Date
April 2 2001
End Date
January 16 2003
Last Update
August 14 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.